Research and Development

Our Research Services

Personalized medicine caters to the needs of individual’s predisposition to a particular disease or condition and allows physicians to prescribe individual and highly effective treatments based on each Patient’s genetic profiles, increasing the effectiveness of treatment and its outcome, while reducing the risk of adverse effects.

 

MolQ has a contemporary facility equipped with advanced platforms for carrying out basic and translational research in the field of cancer and genetic diseases.

 

MolQ is your development partner for new diagnostic technologies from proof of concept through to validation, regulatory approval and launch. MolQ has extensive expertise with method development, assay validation and integration of biomarkers into drug development and clinical trials, in vitro diagnostics and point of care testing devices. Our R&D team can assist with validation and verification studies to demonstrate the performance characteristics as well as the clinical utility of laboratory, diagnostics methods and assays.

 

Our team works with clients in a truly collaborative manner providing support at every stage of development:

  • Discovery phase
  • Proof of concept & mechanism
  • Clinical trial & utility studies

 

Biomarkers Identification, Validation and Assay Development

 

MolQ offers exceptional expertise in biomarker identification, validation and method development . We prowess in tissue-, cell-, and fluid-based biomarker assay development. Our expertise include:

 

  • Biochemistry
  • Genomics
  • Cell biology
  • Biomarker discovery
  • Microbiology
  • Molecular biology
  • Immunology

 

Development and Validation Services

 

MolQ has specialized expertise in the discovery, development and validation of prognostic, diagnostic and theranostic biomarker assays.

 

  • Conventional and multiplex immunoassays (chip- and bead-based)
  • Histopathological markers (Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC)
  • Genetic markers (Polymerase chain reaction (PCR), microarrays, conventional and Next Generation sequencing (NGS)
  • Point of Care applications

Next Generation Sequencing

 

MolQ offers next generation sequencing services using Illumina’s platforms. Different areas for NGS based applications include:

 

  • Whole Genome sequencing
  • Selective Exome sequencing
  • Transcriptome sequencing
  • Targeted sequencing

Epigenetics, Methylation and Gene Regulation

 

MolQ offers expertise across a broad variety of platforms for epigenetics analysis, and provides assistance in developing approaches for studies such as:

 

  • Quantitative methylation analysis
  • Targeted gene methylation analysis
  • Discovery and profiling of microRNAs and other non-coding RNA
  • DNA-protein interaction analysis
Blending technology with research

MolQ has access to state-of-the-art instrumentation and diagnostic platforms, including:

 

Proteomics based:

 

  • Light Chromatography- Mass Spectroscopy (LC-MS)
  • Enzyme linked immunosorbent assay (ELISA), CLIA, Immunoassay Platforms
  • Iummnohistochemistry (IHC)
  • Western blotting
  • Polyclonal and monoclonal antibody production

Genomics based

 

MolQ’s researchers are world-renowned experts in genomic sciences, and have extensive experience in experimental design and analysis for both research and clinical samples. Our expert genomics team is ready to assist in finding the right protocols for your research challenges.

 

  • Array-based platforms for genotyping and methylation analysis
  • Real-time Quantitative Polymerase Chain Reaction(PCR)/Real Time-PCR
  • Fluorescent in situ hybridization (FISH)/Chromogenic in situ hybridisation (CISH)/RNA in situ hybridization (RISH)
  • Conventional and Next Generation Sequencing (NGS)
  • MolQ offers access to state-of-the-art genomic technology platforms, allowing our clients to expand their R&D horizons through a full range of applications, including:
  • Clinical diagnostics
  • Biomarker discovery and validation
  • Custom assay development
  • Companion diagnostics
  • Patient stratification for clinical trials

Cell biology based:

 

  • Proliferation/Survival/Invasion Assays
  • Advanced bioimaging
  • Flow Cytometry
  • Cloning
  • Primary culture establishment
  • Cell Line establishment and immortalization

Biochemical

 

  • Enzyme assays
  • Drug level monitoring
  • Substance abuse screening
  • Drug sensitivity assays
  • Toxin analysis

Histology Research Services

 

MolQ offers a full range of routine and customized histology services. MolQ specializes in all aspects of histopathology, immunohistochemistry, and image analysis. We assist in planning, execution, validation and implementation phases of an experiment/project. We offer histology services at any stage of a project, customized specifically to each project’s requirements.

Histological Services

 

Processing of samples in different embedding material:

 

  • Plastic/Resin
  • Paraffin
  • Frozen

 

Cutting and Staining of different tissue types:

 

  • Soft and hard tissues
  • Whole mount preparation and cutting

 

Staining Procedures:

 

  • H&E
  • Fluorescence in situ hyridization staining/In situ hybridization
  • Special stains
  • Whole mount staining
  • RNA and DNA studies

 

Tissue Micro-arrays:

 

  • Designing
  • Construction
  • Cutting, staining and scoring

 

Immunohistochemistry:

 

  • Optimization and staining of routine and new antibodies (Individual slides, TMAs)
  • Immunocytochemical and Immunofluorescence staining
  • Dual or triple staining

 

Image Analysis

 

  • Digitalized imaging of slides and TMA using Brightfield and Fluorescence Microscopy
  • Image analysis using state of art techniques
  • Pathological scoring, analysis and report generation
Previous research work

 

  • To develop, evaluate, and validate biomarkers that may enable earlier detection and risk assessment of Pancreatic Cancer.
  • Evaluation of prognostic and predictive Molecular Markers in Gall Bladder Cancer. In collaboration with King George Medical University, Lucknow
  • Development of Cetuximab Biosimilar human Anti-EGFR antibody.
  • Development of improved kit for detection of mycobacterium tuberculosis specific to Asian population.

 

Projects undergoing (For Diagnostic lab services, Kit development and production)

 

  • IHC based diagnostic markers:  
    • Breast Cancer- ER, PR, Her2neu
    • Medulloblastoma- beta catenin
    • Prostate Cancer- PIN
  • FISH based diagnostic markers: Her2neu, Bcr-abl
  • PCR-based diagnostic markers: Bcr-abl (quantitative), K-ras codon12/13, Braf V600E